Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial

Fig. 1

Cumulative incidence of MACE by study treatment group and insulin treatment category. Kaplan–Meier plots showing the cumulative incidence of MACE in the apabetalone and placebo groups, according to insulin treatment category. Hazard ratio are calculated by Cox proportional hazards models, stratified by country (countries with fewer than 100 patients combined) and statin agent (atorvastatin or rosuvastatin). Solid lines, insulin-treated. Dashed lines, not insulin-treated. MACE, major adverse cardiovascular events. Apabetalone had a larger effect on absolute risk of MACE among insulin-treated than not insulin-treated patients (quantitative interaction P = 0.006)

Back to article page